A look back at the most influential drug approvals of 2005.
Explore the source record for details and available documents.
Amyloid↗
Biomedical subjects
Gary Laustsen
Publications and source records attributed to Gary Laustsen.
Ramelteon (rozerem) a novel approach for insomnia treatment.
Explore the source record for details and available documents.
Administration, Oral↗
Glumetza: once-a-day dosing for management of type 2 diabetes.
Explore the source record for details and available documents.
Delayed-Action Preparations↗
RotaTeq for prevention of rotavirus gastroenteritis.
Explore the source record for details and available documents.
Administration, Oral↗
2004 drug approval highlights: FDA update.
Explore the source record for details and available documents.
Administration, Cutaneous↗
Duloxetine fights major depressive disorder.
Explore the source record for details and available documents.
Antidepressive Agents↗
Symlin for adults with type 1 and type 2 diabetes.
Explore the source record for details and available documents.
Adult↗
Eszopiclone (lunesta) for treatment of insomnia.
Explore the source record for details and available documents.
Azabicyclo Compounds↗
Glumetza offers once-a-day dosing for type 2 diabetes patients.
Explore the source record for details and available documents.
Contraindications↗
Health care and Earth care--part 2.
Explore the source record for details and available documents.
Colorado↗
Drug approval highlights for 2003.
In the past 12 months, the FDA has approved important new pharmaceutical drugs and devices of particular interest to primary health care providers. The drugs include: Oxytrol (for urinary incontinence), Valtrex (for reducing the risk of heterosexual transmission of genital herpes), Femring (for vaginal delivery of hormone therapy), Uroxatral (for benign prostatic hypertrophy), Levitra (for erectile dysfunction), Flumist (for preventing influenza), Xolair (for asthma), Raptiva (for psoriasis), Cubicin (for skin infections), Crestor (for hypercholesterolemia), and Coreg (for severe heart failure).
Acyclovir↗
Inspra improves survival for CHF patients.
Explore the source record for details and available documents.
Dose-Response Relationship, Drug↗
Caduet treats two cardiovascular conditions at once.
Explore the source record for details and available documents.
Amlodipine↗
Telithromycin (Ketek) for community-acquired respiratory tract infections.
Explore the source record for details and available documents.
Community-Acquired Infections↗
Oxytrol approved for overactive bladder.
Explore the source record for details and available documents.
Administration, Cutaneous↗
Environment, ecosystems, and ecological behavior: a dialogue toward developing nursing ecological theory.
Current epistemological foundations of nursing theory incorporate minimal ecology theory. The purpose of this article is to present a nursing ecological theory with a goal to broaden current nursing perspectives by incorporating expanded concepts of global ecosystems, communities, and interrelationships derived from ecological sciences. A theory derivation process is utilized, and a nursing ecological model is proposed. Nurses face a challenge to translate global environment concern and ecological beliefs into professional activities. Elucidating a nursing ecological theory may guide our profession toward new directions in holistic care and will be good for the care of our patients, profession, and the Earth.
Concept Formation↗